Rayzebio Is A Clinical Stage Biotech Company Specializing In Radiopharmaceutical Therapeutics For Targeted Cancer Treatmentsthe Company Focuses On Using Actinium 225A Potent Alpha Emitting Isotopeto Deliver Radiation Directly To Tumors While Minimizing Damage To Healthy Tissuesrayzebio S Approach Emphasizes Precision Medicineparticularly For Solid Tumors And Metastatic Cancers The Company S Lead Drug Candidateryz101Is Currently In Phase 3 Trials For Gastroenteropancreatic Neuroendocrine Tumors And Is Also Being Developed For Small Cell Lung Canceradditionallyrayzebio Is Advancing A Preclinical Program Targeting Glypican 3Which Is Overexpressed In Certain Cancerswith A Robust Pipeline Of Drug Candidates And A Strong Emphasis On In House Research And Developmentrayzebio Aims To Enhance Patient Outcomes Through Innovative Therapies In December 2023Rayzebio Was Acquired By Bristol Myers Squibbwhich Positions The Company To Scale Its Clinical Programs And Broaden The Commercialization Of Its Therapies Within An Established Oncology Network
No conferences found for this company.
| Company Name | Rayzebio Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
